8-K: Windtree Therapeutics Secures $250,000 in Financing Through Convertible Promissory Note

Windtree Therapeutics enters into a material agreement, issuing a convertible promissory note to institutional investors for gross proceeds of $250,000.

Summary

• Windtree Therapeutics, Inc. has agreed to issue and sell 20% OID Senior Secured Promissory Notes to two institutional investors.
• The aggregate principal amount of the Notes is $312,500, issued at an original issue discount of 20%, resulting in gross proceeds of $250,000 for the company.
• The Notes were issued in a private offering.
• The Notes will mature on January 4, 2026, with a 10% per annum interest rate, payable monthly in cash.
• A mandatory pre-payment is required, equal to 25% of the gross proceeds from a common stock purchase agreement expected around June 26, 2025, with a 120% pre-payment premium.
• The Notes are convertible into Common Stock at a price of $1.10 per share, subject to adjustment.
• The company must file a registration statement for the resale of securities issuable under the Note within 20 calendar days.
• If the company issues Common Stock or equivalents at a lower price than the Conversion Price, the Conversion Price will be reduced accordingly.
• Upon an Event of Default, the Notes will accrue interest at an additional rate of 2% per month (24% per annum) or the maximum rate permitted by law.
• The Notes contain customary covenants providing for a variety of obligations on the part of the Company.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the financing provides needed capital, the terms are not particularly favorable for the company, indicating a higher risk profile.

Positives

• Windtree Therapeutics secures immediate funding of $250,000.
• The notes have a defined maturity date of January 4, 2026, providing a clear repayment timeline.
• The conversion feature at $1.10 per share offers potential upside for investors if the stock price increases.
• The mandatory prepayment clause linked to a future stock purchase agreement could accelerate debt repayment.
• The company has the option to prepay the notes upon a Qualified Financing, which could reduce the overall interest expense.

Negatives

• The 20% original issue discount significantly reduces the net proceeds received by Windtree Therapeutics.
• The 10% interest rate increases the cost of capital for the company.
• The mandatory prepayment premium of 120% adds a substantial cost if the triggering event occurs.
• The potential for downward adjustment of the conversion price could lead to significant dilution for existing shareholders.
• The high default interest rate of 24% per annum creates a significant financial risk in case of non-compliance.

Risks

• Failure to meet the obligations under the Notes could trigger an Event of Default, leading to accelerated repayment and higher interest rates.
• The potential dilution from the conversion of the Notes could negatively impact existing shareholders.
• The company's ability to meet the mandatory prepayment requirement depends on the successful completion of the common stock purchase agreement.
• The company's financial performance may not improve sufficiently to allow for repayment or conversion of the Notes before the maturity date.
• The company's failure to file the registration statement within 20 days could trigger penalties or legal action.

Future Outlook

The company anticipates a common stock purchase agreement around June 26, 2025, which will trigger a mandatory prepayment of the notes. The company is also required to file a registration statement within 20 days for the resale of securities issuable under the Note.

Management Comments

• There are no direct management quotes in the document, but the filing of the 8-K indicates management's adherence to regulatory requirements and transparency with investors.

Industry Context

Small biotech companies often use convertible notes to raise capital quickly, especially when traditional financing options are limited. The terms of the note, including the OID and conversion price, reflect the perceived risk and potential upside of the company.

Comparison to Industry Standards

• The 20% OID is relatively high, suggesting that investors perceive a significant risk in Windtree Therapeutics.
• Comparable companies raising capital through convertible notes often have OIDs in the range of 0-10%.
• The 10% interest rate is also on the higher end, reflecting the risk profile of the company.
• The conversion price of $1.10 will be compared to the current market price of the stock to determine the attractiveness of the conversion feature.
• The mandatory prepayment clause is somewhat unusual and suggests that the investors have confidence in the company's ability to secure additional funding in the near future.

Stakeholder Impact

• Shareholders may experience dilution if the notes are converted into common stock.
• Employees may benefit from the increased financial stability provided by the financing.
• Customers and suppliers may see continued operations and partnerships due to the company's access to capital.
• Creditors may be impacted by the new debt obligations and the security agreement.

Next Steps

• Windtree Therapeutics must file a registration statement on Form S-1 within 20 calendar days for the resale of registrable securities under the Note.
• The company needs to manage its cash flow to meet the monthly interest payments and the potential mandatory prepayment.
• The company needs to successfully execute the common stock purchase agreement expected around June 26, 2025.
• The company needs to monitor the conversion price and potential dilution from the conversion of the Notes.

Key Dates

Keywords

convertible note, financing, promissory note, Windtree Therapeutics, institutional investors, OID, conversion price, registration statement, default, prepayment